AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23580693 — intervention group
Group type: EXPERIMENTAL
Intervention: Age ≤ 49
Number of subjects: 2411
Study 23581634 — intervention group
Group type: EXPERIMENTAL
Intervention: HuCNS-SC transplantation (low-dose)
Number of subjects: 6
Study 23581634 — intervention group
Group type: EXPERIMENTAL
Intervention: HuCNS-SC transplantation (high-dose)
Number of subjects: 6
Study 23581758 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifurcated endograft
Number of subjects: 1172
Study 23581758 — intervention group
Group type: COMPARATOR
Intervention: Aortouni-iliac (AUI) stent-grafting
Number of subjects: 1172
Study 23582142 — intervention group
Group type: EXPERIMENTAL
Intervention: Extensively hydrolyzed casein formula (EHCF), n = 55
Number of subjects: 260
Study 23582142 — intervention group
Group type: EXPERIMENTAL
Intervention: EHCF + Lactobacillus rhamnosus GG (LGG), n = 71
Number of subjects: 260
Study 23582142 — intervention group
Group type: COMPARATOR
Intervention: Hydrolyzed rice formula (RHF), n = 46
Number of subjects: 260
Study 23582142 — intervention group
Group type: COMPARATOR
Intervention: Soy formula, n = 55
Number of subjects: 260
Study 23582142 — intervention group
Group type: COMPARATOR
Intervention: Amino acid based formula, n = 33
Number of subjects: 260
Study 23582472 — intervention group
Group type: EXPERIMENTAL
Intervention: High-confidence NBI prediction for polyps ≤5 mm
Number of subjects: 278
Study 23582472 — intervention group
Group type: EXPERIMENTAL
Intervention: High-confidence NBI for adenomatous histology
Number of subjects: 278
Study 23582881 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus 10mg daily
Number of subjects: 37
Study 23583249 — intervention group
Group type: EXPERIMENTAL
Intervention: LAA closure with the Watchman device
Number of subjects: 150
Study 23583440 — intervention group
Group type: EXPERIMENTAL
Intervention: Trametinib 2mg daily with standard gemcitabine dosing (1000 mg/m(2) IV Days 1, 8, and 15 of 28-day cycles)
Number of subjects: 31
Study 23583440 — intervention group
Group type: COMPARATOR
Intervention: Standard gemcitabine dosing (1000 mg/m(2) IV Days 1, 8, and 15 of 28-day cycles)
Number of subjects: 31
Study 23584252 — intervention group
Group type: EXPERIMENTAL
Intervention: HZ/su vaccine (two doses according to a 0, 2-month schedule)
Number of subjects: 20
Study 23584562 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with aortic valve calcification
Number of subjects: 104
Study 23584562 — intervention group
Group type: COMPARATOR
Intervention: Patients without aortic valve calcification
Number of subjects: 104
Study 23584790 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation (NMES) for 1 hour/day, 5 days/week for 2-3 weeks
Number of subjects: 32
Study 23584790 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation (NMES)
Number of subjects: 32
Study 23584790 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional swallowing rehabilitation (50 min/day, 3 days/week for 4 weeks)
Number of subjects: 32
Study 23585526 — intervention group
Group type: EXPERIMENTAL
Intervention: Deferasirox
Number of subjects: 72
Study 23585526 — intervention group
Group type: COMPARATOR
Intervention: Control (non-responders)
Number of subjects: 72
Study 23585527 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil therapy
Number of subjects: 10
Study 23585999 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive aripiprazole
Number of subjects: 3
Study 23585999 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3
Study 23585997 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive aripiprazole
Number of subjects: 0
Study 23585997 — intervention group
Group type: COMPARATOR
Intervention: Adjunctive placebo
Number of subjects: 0
Study 23586347 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial antibiotic treatment modification
Number of subjects: 2039
Study 23586347 — intervention group
Group type: EXPERIMENTAL
Intervention: Streamlining (de-escalation) of therapy
Number of subjects: 2039
Study 23586347 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean length of hospital stay
Number of subjects: 2039
Study 23586347 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall mortality
Number of subjects: 2039
Study 23587148 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative chemosensitivity testing using FDG-PET/CT before and after one course of FOLFOX
Number of subjects: 0
Study 23587148 — intervention group
Group type: COMPARATOR
Intervention: 6 months of adjuvant FOLFOX treatment
Number of subjects: 0
Study 23587983 — intervention group
Group type: EXPERIMENTAL
Intervention: OROS methylphenidate
Number of subjects: 121
Study 23588536 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentostatin 1.5 mg/m(2)/day intravenously on days 1-3 of each 14-day cycle
Number of subjects: 8
Study 23588536 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentostatin 0.75 mg/m(2) after dose reduction
Number of subjects: 8
Study 23588536 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentostatin treatment
Number of subjects: 8
Study 23589169 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight reduction and increased physical activity
Number of subjects: 0
Study 23589215 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD8931 40 mg bid
Number of subjects: 28
Study 23589215 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD8931 80 mg bid
Number of subjects: 28
Study 23589215 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD8931 160 mg bid
Number of subjects: 28
Study 23589215 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD8931 240 mg bid
Number of subjects: 28
Study 23589215 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD8931 300 mg bid
Number of subjects: 28
Study 23589215 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD8931 (all doses)
Number of subjects: 28
Study 23589315 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab (initial dose of 400 mg/m(2) on day 1 followed by 250 mg/m(2) weekly)
Number of subjects: 0
Study 23589410 — intervention group
Group type: EXPERIMENTAL
Intervention: Telehealth interventions for mental health treatment
Number of subjects: 769
Study 23589410 — intervention group
Group type: EXPERIMENTAL
Intervention: Barriers to mental health care utilization
Number of subjects: 769
Study 23590701 — intervention group
Group type: EXPERIMENTAL
Intervention: PB 500 mg twice daily with vitamin D3 5000 IU once daily (Group-II)
Number of subjects: 0
Study 23590701 — intervention group
Group type: EXPERIMENTAL
Intervention: PB 250 mg twice daily (Group-I)
Number of subjects: 0
Study 23590701 — intervention group
Group type: EXPERIMENTAL
Intervention: PB 500 mg twice daily (Group-I)
Number of subjects: 0
Study 23590701 — intervention group
Group type: EXPERIMENTAL
Intervention: PB 500 mg twice daily (Group-IV)
Number of subjects: 0
Study 23590701 — intervention group
Group type: EXPERIMENTAL
Intervention: PB 500 mg twice daily (Group-I), PB 500 mg twice daily (Group-II), vitamin D3 5000 IU once daily (Group-V)
Number of subjects: 0
Study 23591447 — intervention group
Group type: EXPERIMENTAL
Intervention: U3-1287 (20 mg/kg every 2 weeks)
Number of subjects: 57
Study 23591447 — intervention group
Group type: EXPERIMENTAL
Intervention: U3-1287
Number of subjects: 57
Study 23592303 — intervention group
Group type: EXPERIMENTAL
Intervention: Successful medical management of the first episode of uncomplicated diverticulitis
Number of subjects: 280
Study 23592303 — intervention group
Group type: EXPERIMENTAL
Intervention: Raised serum level of C-reactive protein (over 240 mg/l) during the first attack
Number of subjects: 280
Study 23592699 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative docetaxel/platin/fluoropyrimidine-based chemotherapy
Number of subjects: 120
Study 23592699 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-pCR patients)
Number of subjects: 120
Study 23593142 — intervention group
Group type: EXPERIMENTAL
Intervention: ORMD-0801 oral insulin capsules (8 mg insulin), self-administered three times daily before meals
Number of subjects: 8
Study 23593305 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma levels of CXC-chemokine interferon-inducible protein-10
Number of subjects: 289
Study 23593305 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma levels of C-reactive protein
Number of subjects: 289
Study 23593305 — intervention group
Group type: EXPERIMENTAL
Intervention: High levels of CC-chemokine ligand 21
Number of subjects: 289
Study 23593305 — intervention group
Group type: EXPERIMENTAL
Intervention: High levels of pentraxin 3
Number of subjects: 289
Study 23594832 — intervention group
Group type: EXPERIMENTAL
Intervention: Distance-based training intervention for pediatricians
Number of subjects: 647
Study 23595039 — intervention group
Group type: EXPERIMENTAL
Intervention: Nylon-flocked protocol cytology
Number of subjects: 58
Study 23595039 — intervention group
Group type: COMPARATOR
Intervention: Dacron protocol cytology
Number of subjects: 58
Study 23595039 — intervention group
Group type: COMPARATOR
Intervention: Dacron protocol
Number of subjects: 58
Study 23595275 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant Sema3A (chemorepellent) added to demyelinated lesions
Number of subjects: 0
Study 23595275 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant Sema3F (chemoattractant) added to demyelinated lesions
Number of subjects: 0
Study 23595275 — intervention group
Group type: EXPERIMENTAL
Intervention: Transgenic mice with reduced Sema3A expression
Number of subjects: 0
Study 23595875 — intervention group
Group type: EXPERIMENTAL
Intervention: Low folate status
Number of subjects: 522
Study 23595875 — intervention group
Group type: COMPARATOR
Intervention: High folate status
Number of subjects: 522
Study 23595877 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy intake (measured objectively)
Number of subjects: 155
Study 23595877 — intervention group
Group type: COMPARATOR
Intervention: Palatable food intake
Number of subjects: 155
Study 23596180 — intervention group
Group type: COMPARATOR
Intervention: Normal Glucose Tolerance (NGT)
Number of subjects: 1264
Study 23596180 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral disposition index
Number of subjects: 1264
Study 23596180 — intervention group
Group type: EXPERIMENTAL
Intervention: HOMA-IR
Number of subjects: 1264
Study 23596247 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical samples tested in triplicate with geno2pheno FPR <10% designated as X4
Number of subjects: 20
Study 23596247 — intervention group
Group type: EXPERIMENTAL
Intervention: Triplicate testing of clinical samples
Number of subjects: 20
Study 23596247 — intervention group
Group type: EXPERIMENTAL
Intervention: Consensus-based approach using median FPR across laboratories
Number of subjects: 20
Study 23596247 — intervention group
Group type: EXPERIMENTAL
Intervention: EQA program for laboratories
Number of subjects: 20
Study 23597147 — intervention group
Group type: EXPERIMENTAL
Intervention: Treprostinil diethanolamine SR (2 mg and 4 mg doses, twice daily)
Number of subjects: 19
Study 23598171 — intervention group
Group type: EXPERIMENTAL
Intervention: Crizotinib 280 mg/m(2) twice daily
Number of subjects: 79
Study 23598292 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision aids (DAs) used during consultations
Number of subjects: 22
Study 23598292 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinician training in DA use and SDM practice
Number of subjects: 22
Study 23598723 — intervention group
Group type: EXPERIMENTAL
Intervention: Systolic Blood Pressure (SBP)
Number of subjects: 0
Study 23598723 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart Rate (HR)
Number of subjects: 0
Study 23598723 — intervention group
Group type: EXPERIMENTAL
Intervention: SBP/HR
Number of subjects: 0
Study 23598723 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in SBP (ΔSBP)
Number of subjects: 0
Study 23598723 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in Heart Rate (ΔHR)
Number of subjects: 0
Study 23598723 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in SBP/HR (ΔSBP/HR)
Number of subjects: 0
Study 23598908 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated Partial Breast Irradiation (APBI) using 3-dimensional conformal radiotherapy (1 week)
Number of subjects: 2800
Study 23598908 — intervention group
Group type: COMPARATOR
Intervention: Standard radiotherapy (6.5 weeks)
Number of subjects: 2800
Study 23598908 — intervention group
Group type: COMPARATOR
Intervention: Hypofractionated radiotherapy (3 weeks)
Number of subjects: 2800
Study 23599019 — intervention group
Group type: EXPERIMENTAL
Intervention: Childhood trauma (physical assault and bullying)
Number of subjects: 1112
Study 23599019 — intervention group
Group type: EXPERIMENTAL
Intervention: Cessation of childhood trauma
Number of subjects: 1112
Study 23599019 — intervention group
Group type: EXPERIMENTAL
Intervention: Severity of bullying
Number of subjects: 1112
Study 23601097 — intervention group
Group type: EXPERIMENTAL
Intervention: Montreal Cognitive Assessment (MoCA)
Number of subjects: 928
Study 23601097 — intervention group
Group type: EXPERIMENTAL
Intervention: Trail Making Test, part A
Number of subjects: 928
Study 23601097 — intervention group
Group type: EXPERIMENTAL
Intervention: Trail Making Test, part B
Number of subjects: 928
Study 23601097 — intervention group
Group type: EXPERIMENTAL
Intervention: Trails A and B completion times
Number of subjects: 928
Study 23601097 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjusted for age, sex, health, vision, mood, and physical functioning
Number of subjects: 928
Study 23601097 — intervention group
Group type: EXPERIMENTAL
Intervention: Situational Driving Frequency and Avoidance scales
Number of subjects: 928
Study 23601750 — intervention group
Group type: EXPERIMENTAL
Intervention: Awake anesthesia with thoracic epidural
Number of subjects: 0
Study 23601750 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 23602437 — intervention group
Group type: EXPERIMENTAL
Intervention: Salivirus
Number of subjects: 454
Study 23602437 — intervention group
Group type: EXPERIMENTAL
Intervention: Saffold virus
Number of subjects: 454
Study 23602437 — intervention group
Group type: EXPERIMENTAL
Intervention: Aichi virus
Number of subjects: 454
Study 23602437 — intervention group
Group type: COMPARATOR
Intervention: Cosavirus
Number of subjects: 454
Study 23602655 — intervention group
Group type: EXPERIMENTAL
Intervention: 2D-Mercy TAPE
Number of subjects: 624
Study 23602655 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D-Mercy TAPE
Number of subjects: 624
Study 23602655 — intervention group
Group type: COMPARATOR
Intervention: Broselow method
Number of subjects: 624
Study 23602668 — intervention group
Group type: EXPERIMENTAL
Intervention: MEDI-534 vaccine at 10(6)TCID50
Number of subjects: 49
Study 23602668 — intervention group
Group type: EXPERIMENTAL
Intervention: MEDI-534 vaccine
Number of subjects: 49
Study 23602777 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel 75 mg daily
Number of subjects: 100
Study 23602777 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel 75 mg daily with HPR (PRU ≥234)
Number of subjects: 100
Study 23603153 — intervention group
Group type: EXPERIMENTAL
Intervention: Advanced life support (ALS)
Number of subjects: 311
Study 23603914 — intervention group
Group type: EXPERIMENTAL
Intervention: TT3b (with additional lenalidomide)
Number of subjects: 1080
Study 23603914 — intervention group
Group type: EXPERIMENTAL
Intervention: TT3a (with bortezomib, thalidomide)
Number of subjects: 1080
Study 23603914 — intervention group
Group type: COMPARATOR
Intervention: Control arm of TT2
Number of subjects: 1080
Study 23604180 — intervention group
Group type: EXPERIMENTAL
Intervention: hs-cTnT Roche
Number of subjects: 2072
Study 23604180 — intervention group
Group type: EXPERIMENTAL
Intervention: hs-cTnI Siemens
Number of subjects: 2072
Study 23604180 — intervention group
Group type: EXPERIMENTAL
Intervention: hs-cTnI Beckman Coulter
Number of subjects: 2072
Study 23604180 — intervention group
Group type: EXPERIMENTAL
Intervention: hs-cTnI Abbott
Number of subjects: 2072
Study 23604435 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg isotopically labeled cyanidin-3-glucoside
Number of subjects: 8
Study 23605145 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise intervention
Number of subjects: 302
Study 23606485 — intervention group
Group type: EXPERIMENTAL
Intervention: Men with DM
Number of subjects: 27
Study 23606485 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 27
Study 23606485 — intervention group
Group type: EXPERIMENTAL
Intervention: Men with DM with RE
Number of subjects: 27
Study 23606485 — intervention group
Group type: EXPERIMENTAL
Intervention: Men with DM without RE
Number of subjects: 27
Study 23606485 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetics with RE
Number of subjects: 27
Study 23606485 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-diabetics and diabetics without RE
Number of subjects: 27
Study 23606702 — intervention group
Group type: EXPERIMENTAL
Intervention: Abatacept
Number of subjects: 0
Study 23606736 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive domain deficits (two or more domain deficits)
Number of subjects: 168
Study 23606736 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive domain deficits
Number of subjects: 168
Study 23606736 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed cerebral infarction
Number of subjects: 168
Study 23608775 — intervention group
Group type: EXPERIMENTAL
Intervention: MACE service
Number of subjects: 173
Study 23608775 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 173
Study 23609401 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended release methylphenidate
Number of subjects: 0
Study 23609405 — intervention group
Group type: EXPERIMENTAL
Intervention: Ziprasidone
Number of subjects: 9
Study 23609828 — intervention group
Group type: EXPERIMENTAL
Intervention: HLA class I haplotype (HLA-A2) peptide vaccine
Number of subjects: 14
Study 23609828 — intervention group
Group type: EXPERIMENTAL
Intervention: HLA class II haplotype (DR4, DP4) peptide vaccine
Number of subjects: 14
Study 23609828 — intervention group
Group type: EXPERIMENTAL
Intervention: Peptides presented by both Class I and II haplotypes
Number of subjects: 14
Study 23609828 — intervention group
Group type: EXPERIMENTAL
Intervention: NY-ESO-1 specific T-cell response
Number of subjects: 14
Study 23610059 — intervention group
Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (RYGB)
Number of subjects: 20
Study 23610059 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic adjustable gastric banding (LAGB)
Number of subjects: 20
Study 23610059 — intervention group
Group type: COMPARATOR
Intervention: Both RYGB and LAGB
Number of subjects: 20
Study 23610060 — intervention group
Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (RYGB)
Number of subjects: 25
Study 23610060 — intervention group
Group type: COMPARATOR
Intervention: Very low-calorie diet (VLCD) of 500 kcal/day
Number of subjects: 25
Study 23610104 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast MRI
Number of subjects: 148
Study 23610104 — intervention group
Group type: COMPARATOR
Intervention: Mammogram
Number of subjects: 148
Study 23610104 — intervention group
Group type: EXPERIMENTAL
Intervention: Both MRI and Mammogram
Number of subjects: 148
Study 23610116 — intervention group
Group type: EXPERIMENTAL
Intervention: MET inhibition
Number of subjects: 0
Study 23610374 — intervention group
Group type: EXPERIMENTAL
Intervention: Virus-specific T cell (VST) lines administered to patients (n = 50)
Number of subjects: 50
Study 23610374 — intervention group
Group type: EXPERIMENTAL
Intervention: Virus-specific T cell (VST) lines for cytomegalovirus (n = 23)
Number of subjects: 50
Study 23610374 — intervention group
Group type: EXPERIMENTAL
Intervention: Virus-specific T cell (VST) lines for adenovirus (n = 18)
Number of subjects: 50
Study 23610374 — intervention group
Group type: EXPERIMENTAL
Intervention: Virus-specific T cell (VST) lines for EBV (n = 9)
Number of subjects: 50
Study 23611709 — intervention group
Group type: EXPERIMENTAL
Intervention: Zenith p-branch device (standard fenestrated endovascular graft); off-the-shelf design used for treatment.
Number of subjects: 16
Study 23611902 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive media treatment for depression (6 sessions of problem-solving therapy)
Number of subjects: 14
Study 23611902 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group (no treatment for 6 weeks)
Number of subjects: 14
Study 23611993 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrically elicited visual evoked potentials (eVEPs)
Number of subjects: 4
Study 23612366 — intervention group
Group type: EXPERIMENTAL
Intervention: Squire's Quest! II video game promoting fruit and vegetable consumption
Number of subjects: 400
Study 23612366 — intervention group
Group type: EXPERIMENTAL
Intervention: Squire's Quest! II video game
Number of subjects: 400
Study 23612462 — intervention group
Group type: EXPERIMENTAL
Intervention: InsuOnline (educational game)
Number of subjects: 128
Study 23612462 — intervention group
Group type: COMPARATOR
Intervention: Traditional instructional activities (lecture and group discussion)
Number of subjects: 128
Study 23612502 — intervention group
Group type: EXPERIMENTAL
Intervention: Myocardial contrast echocardiography (MCE) measuring relative myocardial blood volume (rBV) at rest
Number of subjects: 45
Study 23612502 — intervention group
Group type: EXPERIMENTAL
Intervention: Myocardial contrast echocardiography (MCE) measuring exchange rate β at rest
Number of subjects: 45
Study 23612502 — intervention group
Group type: EXPERIMENTAL
Intervention: Myocardial contrast echocardiography (MCE) for detecting severe CAV
Number of subjects: 45
Study 23612920 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary infusion of autologous bone marrow-derived progenitor cells (BMC)
Number of subjects: 124
Study 23612920 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified, but implied as patients not receiving BMC therapy)
Number of subjects: 124
Study 23613128 — intervention group
Group type: EXPERIMENTAL
Intervention: LY6K-177 peptide vaccine emulsified with Montanide ISA 51
Number of subjects: 6
Study 23613128 — intervention group
Group type: EXPERIMENTAL
Intervention: LY6K-177 peptide vaccine
Number of subjects: 6
Study 23613476 — intervention group
Group type: EXPERIMENTAL
Intervention: Anastrozole
Number of subjects: 45
Study 23613476 — intervention group
Group type: COMPARATOR
Intervention: Control (Tamoxifen)
Number of subjects: 45
Study 23613521 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-azacytidine (AZA) 75 mg/m(2) intravenously daily for 7 days and sorafenib 400 mg orally twice daily continuously; cycles were repeated at ~1-month intervals
Number of subjects: 43
Study 23613797 — intervention group
Group type: EXPERIMENTAL
Intervention: ECG-gated, whole chest CT
Number of subjects: 102